CA3143604A1 - Methods for treatment of subjects with psoriatic arthritis - Google Patents
Methods for treatment of subjects with psoriatic arthritis Download PDFInfo
- Publication number
- CA3143604A1 CA3143604A1 CA3143604A CA3143604A CA3143604A1 CA 3143604 A1 CA3143604 A1 CA 3143604A1 CA 3143604 A CA3143604 A CA 3143604A CA 3143604 A CA3143604 A CA 3143604A CA 3143604 A1 CA3143604 A1 CA 3143604A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- week
- dose
- patient
- tildrakizumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 89
- 201000001263 Psoriatic Arthritis Diseases 0.000 title claims abstract description 64
- 208000036824 Psoriatic arthropathy Diseases 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims description 67
- 229920001184 polypeptide Polymers 0.000 claims description 64
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 64
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 64
- 230000004044 response Effects 0.000 claims description 62
- 230000006872 improvement Effects 0.000 claims description 38
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 29
- 230000009266 disease activity Effects 0.000 claims description 21
- 208000002193 Pain Diseases 0.000 claims description 20
- 206010023232 Joint swelling Diseases 0.000 claims description 18
- 230000009267 minimal disease activity Effects 0.000 claims description 18
- 201000004681 Psoriasis Diseases 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 239000000427 antigen Substances 0.000 abstract description 17
- 102000036639 antigens Human genes 0.000 abstract description 17
- 108091007433 antigens Proteins 0.000 abstract description 17
- 239000012634 fragment Substances 0.000 abstract description 14
- 229950005515 tildrakizumab Drugs 0.000 description 252
- 239000000902 placebo Substances 0.000 description 134
- 229940068196 placebo Drugs 0.000 description 134
- 150000001413 amino acids Chemical group 0.000 description 43
- 238000004458 analytical method Methods 0.000 description 32
- 108010074051 C-Reactive Protein Proteins 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 102100032752 C-reactive protein Human genes 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 210000001503 joint Anatomy 0.000 description 10
- 229940126602 investigational medicinal product Drugs 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 206010042674 Swelling Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000013517 stratification Methods 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 206010064769 Dactylitis Diseases 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000001755 vocal effect Effects 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 201000002661 Spondylitis Diseases 0.000 description 2
- 206010043255 Tendonitis Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000020947 enthesitis Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- SVYNLIRHKQCPNE-UHFFFAOYSA-N 3,4-dihydro-1h-isoquinolin-2-ium-2-ylidenemethanediamine;hydrogen sulfate Chemical compound OS(O)(=O)=O.C1=CC=C2CN(C(=N)N)CCC2=C1 SVYNLIRHKQCPNE-UHFFFAOYSA-N 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100296543 Caenorhabditis elegans pbo-4 gene Proteins 0.000 description 1
- 206010009152 Chronic tonsillitis Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001674788 Pasites Species 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003797 carpal joint Anatomy 0.000 description 1
- 210000000511 carpometacarpal joint Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921015050 | 2019-04-15 | ||
| IN201921015050 | 2019-04-15 | ||
| IN202021004422 | 2020-01-31 | ||
| IN202021004422 | 2020-01-31 | ||
| PCT/IB2020/053565 WO2020212874A1 (en) | 2019-04-15 | 2020-04-15 | Methods for treatment of subjects with psoriatic arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3143604A1 true CA3143604A1 (en) | 2020-10-22 |
Family
ID=72837755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3143604A Pending CA3143604A1 (en) | 2019-04-15 | 2020-04-15 | Methods for treatment of subjects with psoriatic arthritis |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220298233A1 (enExample) |
| EP (1) | EP3956357A4 (enExample) |
| JP (2) | JP7628962B2 (enExample) |
| KR (1) | KR20210140780A (enExample) |
| CN (1) | CN113825768A (enExample) |
| AU (1) | AU2020259375A1 (enExample) |
| BR (1) | BR112021020612A2 (enExample) |
| CA (1) | CA3143604A1 (enExample) |
| IL (1) | IL287213A (enExample) |
| JO (1) | JOP20210279A1 (enExample) |
| MA (1) | MA55729A (enExample) |
| MX (1) | MX2021012652A (enExample) |
| MY (1) | MY210310A (enExample) |
| PH (1) | PH12021552536A1 (enExample) |
| SG (1) | SG11202111056YA (enExample) |
| WO (1) | WO2020212874A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202521154A (zh) * | 2023-08-11 | 2025-06-01 | 大陸商信達生物製藥（蘇州）有限公司 | 既往接受生物製劑治療斑塊狀銀屑病的受試者轉用抗ＩＬ２３ｐ１９抗體治療斑塊狀銀屑病的方法 |
| WO2025051249A1 (zh) * | 2023-09-07 | 2025-03-13 | 信达生物制药(苏州)有限公司 | 一种重组抗IL-23p19抗体治疗中重度银屑病的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7807389B2 (en) * | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| WO2008063213A2 (en) * | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| BRPI0807710B1 (pt) * | 2007-02-23 | 2021-12-14 | Merck Sharp & Dohme Corp | Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica |
| WO2010027766A1 (en) * | 2008-08-27 | 2010-03-11 | Schering Corporation | Lyophilized formulatons of engineered anti-il-23p19 antibodies |
| PT2635601T (pt) * | 2010-11-04 | 2016-09-27 | Boehringer Ingelheim Int | Anticorpos anti-il-23 |
| WO2014004436A2 (en) * | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
-
2020
- 2020-04-15 WO PCT/IB2020/053565 patent/WO2020212874A1/en not_active Ceased
- 2020-04-15 MA MA055729A patent/MA55729A/fr unknown
- 2020-04-15 AU AU2020259375A patent/AU2020259375A1/en active Pending
- 2020-04-15 BR BR112021020612A patent/BR112021020612A2/pt unknown
- 2020-04-15 JO JOP/2021/0279A patent/JOP20210279A1/ar unknown
- 2020-04-15 SG SG11202111056YA patent/SG11202111056YA/en unknown
- 2020-04-15 JP JP2021561000A patent/JP7628962B2/ja active Active
- 2020-04-15 CA CA3143604A patent/CA3143604A1/en active Pending
- 2020-04-15 PH PH1/2021/552536A patent/PH12021552536A1/en unknown
- 2020-04-15 MY MYPI2021005910A patent/MY210310A/en unknown
- 2020-04-15 KR KR1020217037137A patent/KR20210140780A/ko active Pending
- 2020-04-15 MX MX2021012652A patent/MX2021012652A/es unknown
- 2020-04-15 EP EP20790874.0A patent/EP3956357A4/en active Pending
- 2020-04-15 US US17/603,921 patent/US20220298233A1/en active Pending
- 2020-04-15 CN CN202080029205.6A patent/CN113825768A/zh active Pending
-
2021
- 2021-10-12 IL IL287213A patent/IL287213A/en unknown
-
2025
- 2025-01-30 JP JP2025013906A patent/JP2025069284A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021020612A2 (pt) | 2021-12-28 |
| MX2021012652A (es) | 2022-01-24 |
| CN113825768A (zh) | 2021-12-21 |
| KR20210140780A (ko) | 2021-11-23 |
| MY210310A (en) | 2025-09-10 |
| PH12021552536A1 (en) | 2022-07-04 |
| MA55729A (fr) | 2022-02-23 |
| JP2025069284A (ja) | 2025-04-30 |
| US20220298233A1 (en) | 2022-09-22 |
| JP2022529266A (ja) | 2022-06-20 |
| EP3956357A4 (en) | 2023-01-04 |
| EP3956357A1 (en) | 2022-02-23 |
| SG11202111056YA (en) | 2021-11-29 |
| WO2020212874A1 (en) | 2020-10-22 |
| JOP20210279A1 (ar) | 2023-01-30 |
| IL287213A (en) | 2021-12-01 |
| JP7628962B2 (ja) | 2025-02-12 |
| AU2020259375A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240376210A1 (en) | Vedolizumab for the treatment of fistulizing crohn's disease | |
| US11208490B2 (en) | Methods for the treatment of thyroid eye disease | |
| JP2025069284A (ja) | 乾癬性関節炎に罹患している対象者の治療方法 | |
| JP2017521427A (ja) | 改善されたＡβプロトフィブリル結合抗体 | |
| US20240059783A1 (en) | Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders | |
| JP7357646B2 (ja) | 乾癬の治療のための組成物及び方法 | |
| AU2023211042A1 (en) | Methods for treatment of subjects with plaque psoriasis of the scalp | |
| TW202102541A (zh) | 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物 | |
| US20220356261A1 (en) | Treatment for sjögren's syndrome | |
| US20250011417A1 (en) | Methods for the treatment of thyroid eye disease | |
| US12497449B2 (en) | Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists | |
| US20250263476A1 (en) | Dosage regimens for treating multifocal motor neuropathy (mmn) | |
| US20210179702A1 (en) | Method of treating tendinopathy using interleukin-17 (il-17) | |
| RU2852738C1 (ru) | Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17) | |
| EP3952993B1 (en) | Method of treating fumaric acid ester-resistant plaque psoriasis | |
| WO2025146509A1 (en) | Methods of treating multifocal motor neuropathy (mmn) | |
| WO2025106642A1 (en) | Methods for the treatment of thyroid eye disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240412 |